Skip to content
Home
Stock Info
NYSE:IGC
Börse Berlín IGS1.BE
Börse frankfurt IGS1.F
Börse Munich IGS1.MU
Börse Stuttgart IGS1.SG
Press Releases
SEC Filing
Company
Our Team
Governance
ESG
Home
Stock Info
NYSE:IGC
Börse Berlín IGS1.BE
Börse frankfurt IGS1.F
Börse Munich IGS1.MU
Börse Stuttgart IGS1.SG
Press Releases
SEC Filing
Company
Our Team
Governance
ESG
Search
Press Releases
All Years
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
March 12, 2024
Read More →
Promising Results: TGR-63 Enhances Memory in Alzheimer’s Mouse Model
February 28, 2024
Read More →
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a Buy Recommendation and $3.00 Price Target
February 23, 2024
Read More →
IGC Pharma Reports Third Quarter Fiscal 2024 Results
February 16, 2024
Read More →
IGC Pharma Announces TGR-63 Reduces Anxiety in Alzheimer’s Mouse Model
February 1, 2024
Read More →
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
January 23, 2024
Read More →
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial
January 17, 2024
Read More →
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s
December 19, 2023
Read More →
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
December 13, 2023
Read More →
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
December 6, 2023
Read More →
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
November 21, 2023
Read More →
IGC Pharma Reports Second Quarter Fiscal 2024 Results
November 13, 2023
Read More →
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
October 19, 2023
Read More →
IGC Announces Results of its 2023 Annual Stockholders Meeting
August 21, 2023
Read More →
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials
August 14, 2023
Read More →
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico
August 2, 2023
Read More →
